Dive Insight:
While California sequencing company Illumina is larger, Oxford's kept itself relevant and recently attracted new cash to fund an expansion.
Amgen's seen the sequencing...
Long known for its prowess in cardiovascular and respiratory diseases, AstraZeneca has joined its pharmaceutical peers in making a bigger play in oncology.
While the British...
Brain cancers are among the most difficult to treat, as Tocagen's struggles follow late-stage study failures earlier this month from AbbVie and Bristol-Myers Squibb.
The biological...
Dive Insight:
While California sequencing company Illumina is larger, Oxford's kept itself relevant and recently attracted new cash to fund an expansion.
Amgen's seen the sequencing...
Audentes Therapeutics is trying to show Sarepta isn't the only game in town when it comes to DMD. The collaboration with Nationwide's Children Hospital...
The plaques are considered hallmarks of Alzheimer's disease, formed in the brain from sticky clusters of a misfolded protein fragment called beta-amyloid.
For the past...
Despite spending billions on R&D, big pharma doesn't punch its weight in discovering the new molecules that eventually make it to market.
Instead, it's...
PHILADELPHIA — It's not artificial intelligence or creative corporate structures that some of the biopharma industry's leaders see as the best way to boost...
The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...
Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...
